Scleroderma (systemic sclerosis [SSc]) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and varying degrees of vasculopathy that manifest as Raynaud’s disease and, often, painful digital ulcers. Risks of PAH, ILD, and renal crisis are higher in SSc patients than in the general population and underlie a high mortality rate. A complex array of treatments may be used in the management of SSc; systemic immunosuppressants are prescribed to treat ILD and skin fibrosis, while other symptoms (e.g., PAH, vasculopathy, renal crisis) are treated with varying combinations of calcium-channel blockers, endothelin receptor antagonists, PDE-5 inhibitors, prostacyclin analogues, and ACE inhibitors. This content provides context for emerging players seeking to capitalize on the unmet needs in this underserved arena.

Questions Answered

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed SSc patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed SSc patients?
  • What proportion of SSc patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
  • What percentage of SSc patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
  • What are the product-level compliance and persistency rates among drug-treated patients with SSc?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed analysis of brand usage across different lines of therapy using real-world, patient-level claims data, so you can accurately assess your source of business and quantify areas of opportunity for increasing your brand share.

Table of contents

  • Detailed, Expanded Analysis - Treatment Algorithms - Claims Data Analysis (US)
    • Treatment Algorithms Claims Data Analysis Scleroderma (Systemic Sclerosis) US January 2019

Author(s): Ian Love, PhD; John Crowley

Ian is an analyst on the Infectious, Niche, and Rare Diseases team at Decision Resources Group, specializing in niche and rare diseases. Ian conducts primary and secondary research to gauge the market landscapes of these diseases, thoroughly analyzing disease etiology, current treatments, unmet need, and emerging therapies expected to impact their respective markets. He received his doctorate in biomedical sciences from the University of Massachusetts Medical School and his in cell & molecular biology from the Worcester Polytechnic Institute. Prior to joining Decision Resources Group, Dr. Love was an Instructor in the Department of Internal Medicine at Virginia Commonwealth University.

John Crowley, ,  is an analyst in the CNS disorders group at Decision Resources. Prior to joining the company, Dr. Crowley was a postdoctoral associate at Harvard Medical School, where he studied mechanisms regulating the strength and dynamics of synaptic connections. He earned a from the University of Massachusetts Medical School, where he conducted research on the modulation of ion channel function by membrane lipids, and a from Worcester Polytechnic Institute.

Related Reports

Scleroderma (Systemic Sclerosis) | Current Treatment | Detailed, Expanded Analysis (US)

Coming Soon – October 2019 MARKET OUTLOOK Scleroderma (systemic sclerosis [SSc]) is heteroge...

View Details